Targeted overexpression of mitochondrial catalase protects against cancer chemotherapy-induced skeletal muscle dysfunction

The loss of strength in combination with constant fatigue is a burden on cancer patients undergoing chemotherapy. Doxorubicin, a standard chemotherapy drug used in the clinic, causes skeletal muscle dysfunction and increases mitochondrial H(2)O(2). We hypothesized that the combined effect of cancer...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Physiol Endocrinol Metab
Autori principali: Gilliam, Laura A. A., Lark, Daniel S., Reese, Lauren R., Torres, Maria J., Ryan, Terence E., Lin, Chien-Te, Cathey, Brook L., Neufer, P. Darrell
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Physiological Society 2016
Soggetti:
Call for Papers
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5005971/
https://ncbi.nlm.nih.gov/pubmed/27329802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajpendo.00540.2015
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi